Skip to content
Ifosfamide
Ifex, Ifex/mesnex, Ifosfamide/mesna (ifosfamide) is a small molecule pharmaceutical. Ifosfamide was first approved as Ifex on 1988-12-30. It is used to treat b-cell chronic lymphocytic leukemia, breast neoplasms, hodgkin disease, lung neoplasms, and non-hodgkin lymphoma amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ifex (generic drugs available since 2002-05-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ifosfamide
Tradename
Company
Number
Date
Products
IFEXBaxterN-019763 RX1988-12-30
2 products, RLD
Ifosfamide
+
Mesna
Tradename
Company
Number
Date
Products
IFEX/MESNEX KITBaxterN-019763 DISCN1992-10-10
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ifexNew Drug Application2018-07-26
ifosfamideANDA2023-04-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
b-cell chronic lymphocytic leukemia—D015451C91.1
breast neoplasmsEFO_0003869D001943C50
hodgkin disease—D006689C81
lung neoplasms—D008175C34.90
non-hodgkin lymphoma—D008228C85.9
ovarian neoplasmsEFO_0003893D010051C56
pancreatic neoplasmsEFO_0003860D010190C25
precursor cell lymphoblastic leukemia-lymphoma—D054198C91.0
sarcoma—D012509—
stomach neoplasmsEFO_0003897D013274C16
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AA: Nitrogen mustard analogues
— L01AA06: Ifosfamide
HCPCS
Code
Description
J9208
Injection, ifosfamide, 1 gram
Clinical
Clinical Trials
366 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD0125091443241883
Large b-cell lymphoma diffuseD016403C83.3121831—29
Non-hodgkin lymphomaD008228C85.941621121
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.02494—17
Germ cell and embryonal neoplasmsD00937311221116
Burkitt lymphomaD002051C83.715—2—7
Large-cell lymphoma anaplasticD017728C84.634—1—6
T-cell lymphoma peripheralD016411C84.931—1—4
Enteropathy-associated t-cell lymphomaD058527C86.21——1—2
Mediastinal neoplasmsD008479C38.3——11—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.99367—349
NeoplasmsD009369C801583—122
Ovarian neoplasmsD010051EFO_0003893C567135——19
OsteosarcomaD012516594—318
LeukemiaD007938C952106—118
Hodgkin diseaseD006689C818122——16
NeuroblastomaD009447EFO_0000621363—112
Central nervous system neoplasmsD016543482——11
Ewing sarcomaD012512EFO_0000173131—49
Lung neoplasmsD008175C34.90145——9
Show 34 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5018———8
B-cell lymphomaD01639333———5
Follicular lymphomaD008224C8235———5
Urinary bladder neoplasmsD001749C6715———5
Mantle-cell lymphomaD020522C83.133———4
Testicular neoplasmsD013736C6212———3
Embryonal carcinomaD018236—2———2
Brain neoplasmsD001932EFO_0003833C71—1——12
Liver neoplasmsD008113EFO_1001513C22.021———2
T-cell lymphomaD01639921———2
Show 30 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primitive neuroectodermal tumorsD0182421———23
RetinoblastomaD0121751———12
Mycosis fungoidesD009182C84.01————1
ThymomaD0139451————1
T-cell leukemiaD0154581————1
Neoplasm metastasisD009362EFO_00097081————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839HP_0002013R11.1————22
Drug-related side effects and adverse reactionsD064420T88.7————11
NauseaD009325HP_0002018R11.0————11
MedulloblastomaD008527————11
HepatoblastomaD018197C22.2————11
Retinal neoplasmsD019572C69.2————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIFOSFAMIDE
INNifosfamide
Description
Ifosfamide is the simplest member of the class of ifosfamides that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by 2-chloroethyl groups on both the nitrogen atoms respectively. It is a nitrogen mustard alkylating agent used in the treatment of advanced breast cancer. It has a role as an antineoplastic agent, an immunosuppressive agent, an alkylating agent, an environmental contaminant and a xenobiotic.
Classification
Small molecule
Drug classphosphoro-derivatives; isophosphoramide mustard derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=P1(NCCCl)OCCCN1CCCl
Identifiers
PDB—
CAS-ID3778-73-2
RxCUI5657
ChEMBL IDCHEMBL1024
ChEBI ID5864
PubChem CID3690
DrugBankDB01181
UNII IDUM20QQM95Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 17,101 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ifex, Ifosfamide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
101 adverse events reported
View more details